Plenty of biopharmaceutical firms continue to struggle to raise fresh capital under current financial market conditions with drug developer valuations still well below what they were a few years ago and initial public offerings few and far between. However, plenty of private and public companies also have been able to raise big money this year, including Apollo Therapeutics Group Ltd. and Nimbus Therapeutics, Inc., which recently raised $226.5m and $210m, respectively, in venture capital financings.
[Sidebar#SC149012]
